Shijiazhuang Wotai Biotechnology Co., Ltd.

I. Primary Objective: To evaluate the efficacy of the experimental group (randomized to receive lyophilized recombinant human brain natriuretic peptide) compared to the placebo control group in patients with acute heart failure (AHF), using the proportion of subjects whose dyspnea improved within 24 hours as the evaluable indicator. II. Key Secondary Objective: To evaluate the efficacy of the experimental group (randomized to receive lyophilized recombinant human brain natriuretic peptide) compared to the placebo control group in patients with AHF. III. Secondary Objectives: 1. To evaluate the efficacy of the experimental group (randomized to receive lyophilized recombinant human brain natriuretic peptide) compared to the placebo control group in patients with AHF. 2. To explore changes in NT-proBNP levels and quality of life scores after drug administration in the experimental group (randomized to receive lyophilized recombinant human brain natriuretic peptide) and the placebo control group. 3. To evaluate the safety of all AHF patients receiving lyophilized recombinant human brain natriuretic peptide. (The safety of all AHF patients receiving placebo should also be evaluated.)

1. Main purpose: To evaluate the difference in efficacy of the trial group (randomly assigned to receive lyophilized recombinant human brain natriuretic peptide) compared with the placebo control group in AHF patients, using the proportion of subjects with improved dyspnea within 24 hours as the evaluation index. 2. Key secondary purpose: To evaluate the efficacy of the trial group (randomly assigned to receive lyophilized recombinant human brain natriuretic peptide) compared with the placebo control group in AHF patients. 3. Secondary purpose: 1. To evaluate the efficacy of the trial group (randomly assigned to receive lyophilized recombinant human brain natriuretic peptide) compared with the placebo control group in AHF patients. 2. To explore the changes in natriuretic peptide levels after administration in the trial group (randomly assigned to receive lyophilized recombinant human brain natriuretic peptide) and the placebo control group. 3. To evaluate the safety of all AHF patients treated with lyophilized recombinant human brain natriuretic peptide. To evaluate the safety of all AHF patients treated with placebo.